Iveda (IVDA) board resets CEO option exercise price to $0.29

Rhea-AI Filing Summary

Iveda Solutions, Inc. reported that Chief Executive Officer David H. Ly had his stock options repriced by the board. On February 23, 2026, options covering 175,000 shares were granted or awarded, and a separate 175,000-option position was disposed of back to the issuer. According to the disclosure, the repricing set the exercise price at $0.29 per share, while all other option terms remained unchanged. After these offsetting derivative transactions, Ly directly held options to acquire 216,096 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Ly David H.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Options (Right to Buy)	175,000	$0.00	--
Disposition	Options (Right to Buy)	175,000	$0.00	--

Holdings After Transaction: Options (Right to Buy) — 216,096 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ly David H.

(Last) (First) (Middle)

1744 S. VAL VISTA DRIVE,

STE. 213

(Street)

MESA AZ 85204

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Iveda Solutions, Inc. [ IVDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$0.82	12/29/2025		D		175,000		12/29/2025	12/29/2035	Common Stock	175,000	$0.00	216,096	D
Options (Right to Buy)	$0.29(1)	02/23/2026		A		175,000		12/29/2025	12/29/2035	Common Stock	175,000	$0.00	216,096	D

Explanation of Responses:

1. On February 23, 2026, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $0.29 per share. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

	/s/ David H. Ly	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Iveda (IVDA) report for its CEO?

Iveda reported that CEO David H. Ly had a mixed option transaction involving both acquisition and disposition. The board approved an option repricing that adjusted his stock options while keeping all other terms unchanged, reflected as a grant of 175,000 options and a matching 175,000-option disposition.

How many Iveda (IVDA) options were affected in the CEO’s Form 4?

The Form 4 shows 175,000 options reported as a grant or award and 175,000 options reported as a disposition to the issuer. These offsetting moves relate to an option repricing, after which David H. Ly directly held options covering a total of 216,096 shares.

What is the new exercise price of the Iveda (IVDA) CEO’s options?

The CEO’s options were repriced to an exercise price of $0.29 per share. The board approved this change as part of an option repricing, and the filing states that all other terms of the options, such as duration and vesting conditions, remained unchanged.

Did the Iveda (IVDA) CEO buy or sell common shares in this Form 4?

The reported transactions involve derivative securities, specifically options, rather than direct common share purchases or sales. The filing records a grant or award of options and a disposition of options to the issuer as part of the repricing arrangement, with no explicit open-market trades disclosed.

How many Iveda (IVDA) options does the CEO hold after the repricing?

After the reported option repricing transactions, David H. Ly directly held options representing 216,096 shares. This total reflects the post-transaction balance of his derivative holdings, following both the 175,000-option grant or award and the 175,000-option disposition back to the issuer.

Were the Iveda (IVDA) CEO’s option transactions exempt under SEC rules?

Yes. The filing states that the option repricing transactions were exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act. These provisions generally cover certain issuer-related option adjustments and board-approved compensation actions for insiders such as officers and directors.